PRINTER'S NO. 2394

THE GENERAL ASSEMBLY OF PENNSYLVANIA

# HOUSE RESOLUTION

No. 459 Session of 2019

INTRODUCED BY STRUZZI, JOZWIAK, PASHINSKI, PICKETT AND SCHLOSSBERG, SEPTEMBER 3, 2019

REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 3, 2019

A RESOLUTION

Urging the United States Food and Drug Administration to promptly consider guidelines and protocols for the approval of cannabidiol as a product which is legally available for resale.

WHEREAS, The United States is seeing a change in the use of marijuana for medical purposes; and

WHEREAS, Thirty-three states and the District of Columbia have recognized that marijuana may have medical purposes; and

WHEREAS, This Commonwealth is one of the states which has legalized the use of medical marijuana for limited purposes, including serious medical conditions; and

WHEREAS, Under Federal law, the 2018 Farm Bill has created additional questions with respect to the definition of marihuana in Schedule I of the Controlled Substances Act; and

WHEREAS, Cannabidiol (CBD) is a product which can be derived from a variety of marijuana plants, including, industrial hemp; and

WHEREAS, The Federal Government has removed hemp and all parts of the plant from the definition of marihuana in Schedule

I of the Controlled Substances Act; and

WHEREAS, The United States Food and Drug Administration (FDA) has previously approved epidiolex as a medicine which contains CBD; and

WHEREAS, It is unclear whether or not the FDA regulates commercially available CBD; and

WHEREAS, It is in the interest of public safety to have a streamlined and consistent oversight system for CBD and CBD products; therefore be it

RESOLVED, That the House of Representatives of the Commonwealth of Pennsylvania urge the United States Food and Drug Administration to promptly consider guidelines and protocols for approval of cannabidiol as a product which is legally available for resale; and be it further

RESOLVED, That a copy of this resolution be transmitted to the headquarters of the United States Food and Drug Administration at 10903 New Hampshire Avenue, Silver Spring, Maryland 20993.